MLYS Mineralys Therapeutics, Inc.

NASDAQ
$23.37

Mineralys Therapeutics, Inc. (MLYS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Subdued Selling ran below MLYS's own trailing one-year pace, with 54% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 4 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
4
11 transactions
Purchases
$0
0 shares
Sales
$6.5M
237,497 shares
Net activity
-$6.5M
purchases less sales

How much of that selling was preplanned? 54% planned / 46% discretionary

10b5-1 plan sales $3.5M 10 transactions · 133,177 shares
Discretionary sales $3.0M 1 transaction · 104,320 shares

Largest single sale: $3.0M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: March 30, 2026 .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Congleton Jon Chief Executive Officer Sell 10b5-1 75,000 $25.46 $1.9M 528,621 −12.4% of holding
Slingsby Brian Taylor Director Sell 104,320 $28.81 $3.0M 7,805,718 −1.3% of holding
Warren Eric Chief Commercial Officer Sell 10b5-1 7,438 $28.12 $209.1K 38,400 −16.2% of holding
Warren Eric Chief Commercial Officer Sell 10b5-1 7,437 $25.98 $193.2K 38,400 −16.2% of holding
Rodman David Malcom Chief Medical Officer Sell 10b5-1 2,170 $27.09 $58.8K 51,384 −4.1% of holding
Warren Eric Chief Commercial Officer Sell 10b5-1 7,438 $26.87 $199.9K 38,400 −16.2% of holding
Rodman David Malcom Chief Medical Officer Sell 10b5-1 416 $26.53 $11.0K 51,384 −0.8% of holding
Rodman David Malcom Chief Medical Officer Sell 10b5-1 6,349 $26.61 $169.0K 51,384 −11% of holding
Rodman David Malcom Chief Medical Officer Sell 10b5-1 14,058 $27.58 $387.7K 57,733 −19.6% of holding
Congleton Jon Chief Executive Officer Sell 10b5-1 10,700 $27.24 $291.4K 603,621 −1.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.